Table 5.
Frequencies of laboratory tests and patient monitoring visits per patient and model according to the Nigerian DR-TB guidelines
| Model A | Model B | Model C | |||||
|---|---|---|---|---|---|---|---|
| Unit | Frequency in intensive phase | Frequency in continuation phase | Frequency in intensive phase | Frequency in continuation phase | Frequency in intensive phase | Frequency in continuation phase | |
| I. DR-TB Diagnostic tests | |||||||
| GeneXpert | Test | 1 | – | 1 | – | 1 | – |
| Sputum smear | Smear | 1 | – | 1 | – | 1 | – |
| Culture – Liquid | Test | 1 | – | 1 | – | 1 | – |
| 1st and 2nd line DST - Solid culture | Test | 1 | – | 1 | – | 1 | – |
| II. Baseline tests & routine laboratory tests | |||||||
| X-ray | Test | 2 | 2 | 2 | 2 | 2 | 2 |
| ENT consultation | Consult | 1 | – | 1 | – | 1 | – |
| Audiometry test | Test | 9 | – | 9 | – | 9 | – |
| E, U, Cr | Test | 8 | – | 8 | – | 8 | – |
| Thyroid function test | Test | 2 | 2 | 2 | 2 | 2 | 2 |
| LFT | Test | 3 | 4 | 3 | 4 | 3 | 4 |
| HIV Test | Test | 1 | – | 1 | – | 1 | – |
| Pregnancy test | Test | 0.5 | – | 0.5 | – | 0.5 | – |
| III. Drugs | |||||||
| Pyrazinamide 400 mg | Tablet | 972 | 1488 | 972 | 1488 | 972 | 1488 |
| Kanamycin 1 g vial | Vial | 243 | – | 243 | – | 243 | – |
| Levofloxacin 250 mg | Caplet | 729 | 1116 | 729 | 1116 | 729 | 1116 |
| Prothionamide 250 mg | Tablet | 729 | 1116 | 729 | 1116 | 729 | 1116 |
| Cycloserine 250 mg | Capsule | 729 | 1116 | 729 | 1116 | 729 | 1116 |
| Pyridoxine 10 mg | Tablet | 729 | 1116 | 729 | 1116 | 729 | 1116 |
| IV. Inpatient stay | |||||||
| Inpatient hospitalization days | Bed day | 243 | – | 152 | – | – | – |
| V. Outpatient consultations and supervision | |||||||
| Consultation at treatment center /Monthly clinic visit | Visit | – | 12 | 3 | 12 | 8 | 12 |
| Visits to collect medication at DOT center/ DOT at DOT center | Visit | – | 24 | 6 | 24 | 16 | 24 |
| Home visit - by DOT officer | Home visit | – | 24 | 91 | 24 | 243 | 24 |
| Home visit by DR TB focal person | Home visit | – | 12 | 3 | 12 | 8 | 12 |
| Home visit by TBL supervisor | Home visit | – | 12 | 3 | 12 | 8 | 12 |
| Quarterly state team meeting | Meeting | – | 4 | 1 | 4 | 3 | 4 |
| Quarterly state team home visit | Home visit | – | 4 | 2 | 4 | 2 | 4 |
| VI. Follow-up DR-TB testing | |||||||
| Sputum smear | Smear | 8 | 12 | 8 | 12 | 8 | 12 |
| Culture - Liquid | Test | 8 | 6 | 8 | 6 | 8 | 6 |
| 1st and 2nd line DST - Solid culture | Test | 0.2^ | 0 | 0.2^ | 0 | 0.2a | 0 |
List of abbreviations: Cr creatinine, DOT directly observed treatment, DR drug resistant, DST drug susceptibility testing, E electrolytes, ENT ear nose throat, TB tuberculosis, TBL tuberculosis and leprosy, U urea, LFT liver function test,
aA conservative estimate of DR-TB patients who are still culture positive after four months of DR-TB treatment and thus require repeat second-line DST